Caprock Group LLC Buys Shares of 1,632,089 Liquidia Corporation $LQDA

Caprock Group LLC bought a new position in Liquidia Corporation (NASDAQ:LQDA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,632,089 shares of the company’s stock, valued at approximately $37,114,000. Liquidia makes up approximately 0.9% of Caprock Group LLC’s investment portfolio, making the stock its 20th biggest position.

A number of other institutional investors have also modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. KLP Kapitalforvaltning AS boosted its stake in Liquidia by 26.9% in the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $164,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Liquidia in the second quarter worth $775,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Performance

Shares of LQDA opened at $40.54 on Wednesday. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The stock has a 50-day moving average of $37.09 and a two-hundred day moving average of $29.40. The stock has a market cap of $3.53 billion, a P/E ratio of -28.15, a P/E/G ratio of 1.19 and a beta of 0.46. Liquidia Corporation has a one year low of $11.26 and a one year high of $46.67.

Insider Activity

In related news, General Counsel Russell Schundler sold 27,289 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,021,427.27. Following the sale, the general counsel owned 579,394 shares in the company, valued at $21,686,717.42. This represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason Adair sold 688 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $41.65, for a total transaction of $28,655.20. Following the completion of the transaction, the insider owned 211,169 shares in the company, valued at approximately $8,795,188.85. This trade represents a 0.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 252,476 shares of company stock valued at $9,173,435. 30.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and set a $49.00 price objective on shares of Liquidia in a report on Friday, January 9th. Needham & Company LLC upped their target price on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Jefferies Financial Group increased their price target on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).